



---

*This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.*

# Revision of Precautions

## Adrenaline (preparations indicated for emergency supplemental treatment of anaphylactic reactions caused by allergens in vespid venom, food, drugs and other allergens)

March 27, 2018

### **Non-proprietary name**

Adrenaline (preparations indicated for emergency supplemental treatment of anaphylactic reaction caused by allergens in vespid venom, food, drugs, and other allergens)

### **Safety measure**

Precautions should be revised in the package insert.

In the Contraindications section, the following language should be deleted:

Patients receiving the following agents (antipsychotic agents with  $\alpha$ -blocking actions, including butyrophenones and phenothiazines, and  $\alpha$ -blockers)

In the Contraindications for Co-administration subsection of the Interactions section, the following language should be deleted:

Antipsychotic agents with  $\alpha$ -blocking actions (butyrophenones, phenothiazines,

**Pharmaceuticals and Medical Devices Agency**

Office of Safety I

3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan

E-mail: [safety.info@pmda.go.jp](mailto:safety.info@pmda.go.jp)

Published by  
Ministry of Health, Labour and Welfare



Translated by  
Pharmaceuticals and Medical Devices Agency



---

*This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.*

iminodibenzyls, zotepine, risperidone) and  $\alpha$ -blockers

In the Precautions for Co-administration subsection of the Interactions section, the following language should be added (revised language is underlined):

Antipsychotic agents with  $\alpha$ -blocking actions (butyrophenones, phenothiazines, iminodibenzyls, zotepine, risperidone) and  $\alpha$ -blockers

**Pharmaceuticals and Medical Devices Agency**

Office of Safety I

3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan

E-mail: [safety.info@pmda.go.jp](mailto:safety.info@pmda.go.jp)